Clinical Trials Directory

Trials / Unknown

UnknownNCT02864472

Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose

Comparison of Early Intervention of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV Patients With Initial Loading Dose

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Seoul National University Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The aim of this study is to compare the efficacy of early intervention of PDT combination compared with consecutive monthly treatment of intravitreal ranibizumab injections in PCV patients showing insufficient response with initial loading dose.

Detailed description

PCV is generally recognized as a subtype of wet AMD characterized by the presence of aneurysmal orange-red polypoidal lesions with or without branching vascular network (BVN) in the choroidal vasculature as observed on indocyanine angiography (ICGA), representing 13% to 54.7% of newly diagnosed patients with neovascular AMD. Fifty percent of PCV had persistent leakage or recurrent bleeding with poor visual outcome, if left untreated. And in the EVEREST study has shown that synergistic effects of anti-VEGF and vPDT combination: vPDT strongly regress polyp and anti-VEGF control to up-regulation of VEGF induced by vPDT compared to ranibizumab monotherapy in newly diagnosed PCV patients. Additionally, combination offers an opportunity for individualized treatment with potentially fewer treatments and less costs. Therefore, the aim of this study is to compare the efficacy of early intervention of PDT combination compared with consecutive monthly treatment of intravitreal ranibizumab injections in PCV patients showing insufficient response with initial loading dose.

Conditions

Interventions

TypeNameDescription
PROCEDUREPDTPDT and ranibizumab
DRUGRanibizumabRanibizumab
DRUGranibizumab PRNranibizumab PRN

Timeline

Start date
2016-09-01
Primary completion
2018-06-01
Completion
2019-01-01
First posted
2016-08-12
Last updated
2016-08-12

Source: ClinicalTrials.gov record NCT02864472. Inclusion in this directory is not an endorsement.